What is TARA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.16B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for TARA?

P/E (TTM) is n/a and 52-week range is $2.51 to $7.82 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s TARA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for TARA?

The company profile lists net income (TTM) near $-76M, EPS (TTM) near $-1.35 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Protara Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in New York City, New York, US, 56.2M shares outstanding, ISIN US74365U1079 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Protara Therapeutics Inc

$TARA

Health Care · Biotechnology

IR Run Scenarios

$2.75

+3.96%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. The company is headquartered in New York City, New York and currently employs 46 full-time employees. The company went IPO on 2014-10-22. The firm's portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The firm is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin, as well as a Phase II trial in pediatric patients with LMs. TARA-002 is a first-in-class TLR2/NOD2 agonist and novel immunopotentiator derived from inactivated Streptococcus pyogenes. Additionally, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support who are otherwise unable to meet their choline needs via oral or enteral routes.

Employees

Website

protaratx.com/

IPO

2014-10-22

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)